Search results for "Stage"

showing 10 items of 1393 documents

Qol and adherence to i.v. or oral chemotherapy treatment in elderly patients with advanced NSCLC.

2012

e18002 Background: In elderly patients with advanced stage NSCLC the identification of the best treatment-related quality of life becomes the main discriminating endpoint. Methods: In this multicentre study, 53 elderly (≥ 70 yrs) patients with advanced (IIIB-IV) NSCLC were randomly allocated to receive as first-line treatment either Gemcitabine intravenously (1000 mg/m2) or oral Vinorelbine (60 mg/m2) both on days 1 and 8, every 21 days. The primary objective was the evaluation of the QoL, while the secondary one was the assessment of treatment adherence. The EORTC QLQ-C30 v 2.0 and QLQ-LC13 questionnaires have been used to evaluate the quality of life and an “ad hoc” questionnaire for the…

OncologyCancer Researchmedicine.medical_specialtyOncologyQuality of lifeOral chemotherapybusiness.industryInternal medicineAdvanced stagemedicinebusinesshumanitiesSurgeryJournal of Clinical Oncology
researchProduct

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblasto…

2011

BACKGROUND: In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse. METHODS: In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enrolled in the prospective European INES trials. RESULTS: Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients wh…

OncologyCancer Researchmedicine.medical_specialtyPathologyChromosomal AlterationsN-Myc Proto-Oncogene Proteinsegmental chromosome alterationsneuroblastomaNeuroblastomaRecurrenceInternal medicineNeuroblastomamedicineHumansProspective StudiesStage (cooking)Relapse riskProspective cohort studygenomic profileSurvival analysisChromosome AberrationsOncogene ProteinsN-Myc Proto-Oncogene Proteininfantsbusiness.industryInfantNuclear ProteinsGenetics and GenomicsPrognosismedicine.diseaseSurvival AnalysisDoenças GenéticasOncologySegmental Chromosome AlterationsHigh RiskGenomic ProfilebusinessBritish Journal of Cancer
researchProduct

DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective stu…

2002

Purpose: The aim of this study was to determine TP53 and NM23-H1 immunoreactivity, DNA ploidy, and S-phase fraction (SPF) in a series of 160 patients undergoing resective surgery for primary operable colorectal cancer (CRC) and to establish whether these alterations have any clinical value in predicting CRC patients' prognosis. Methods: TP53 and NM23-H1 expressions were evaluated on paraffin-embedded tissue by immunohistochemistry and DNA-ploidy and SPF on frozen tissue by flow-cytometric analysis. Results: The median follow-up time in our study group was 71 months (range 34-115 months). P53 protein expression was associated with distal tumors (P &lt; 0.05) and DNA aneuploid tumors (P &lt; …

OncologyCancer Researchmedicine.medical_specialtyPathologyFlow-cytometric variableTime FactorsTumor suppressor geneColorectal cancerPrognosiSettore MED/06 - Oncologia MedicaColonRectumBiologyAdenocarcinomaDisease-Free SurvivalS PhasePredictive Value of TestsInternal medicinemedicineBiomarkers TumorHumansStage (cooking)Prospective cohort studyMonomeric GTP-Binding ProteinsNeoplasm StagingTP53 expressionHematologyPloidiesGeneral MedicineDNA NeoplasmCell cycleNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseColorectal cancerAdenocarcinoma MucinousImmunohistochemistrySurvival Analysismedicine.anatomical_structureTreatment OutcomeOncologyNucleoside-Diphosphate KinaseImmunohistochemistryLymph NodesTumor Suppressor Protein p53Colorectal NeoplasmsCell DivisionTranscription FactorsJournal of cancer research and clinical oncology
researchProduct

A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.

2013

9026 Background: Lenvatinib is an oral receptor tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT, and PDGFRβ. Melanoma responses in the phase I study led to this multicenter phase II trial of lenvatinib in separate cohorts of BRAF mutant and BRAF wild-type (wt) melanoma to provide an estimate of efficacy and to identify molecular correlates of clinical benefit. Primary analyses of clinical outcomes for the BRAF wt cohort are reported here; the BRAF mutant cohort will be presented at a later date. Methods: Eligible patients (pts) had stage IV or unresectable stage III BRAF wt melanoma with ≥1 prior treatment (26/96 [27%] pts received ≥3 treatments) and no prior VEGF-targeted …

OncologyCancer Researchmedicine.medical_specialtyPathologybusiness.industryKinaseMelanomaPhases of clinical researchmedicine.diseasechemistry.chemical_compoundOncologychemistryInternal medicineCohortToxicityClinical endpointMedicineStage (cooking)businessLenvatinibJournal of Clinical Oncology
researchProduct

HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily.

2013

According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date, the prevalence of HER2 overexpression in Sicilian people with AGC is unknown. Therefore, in the present study, a retrospective immunohistochemical analysis of HER2 was performed in a cohort of 304 AGC samples that were obtained from the archives of 10 Sicilian anatomopathological diagnostic units in order to verify the positive rate of HER2-positive cases. Furthermore, the characteristics of his…

OncologyCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastric adenocarcinoma; HER2 status; Sicily; TrastuzumabHER2 gastric carcinomaSettore MED/08 - Anatomia PatologicaTrastuzumabInternal medicinemedicineStage (cooking)skin and connective tissue diseasesneoplasmsSicilyChemotherapyHER2 status; Sicily; gastric adenocarcinoma; trastuzumabHER2 statusbusiness.industryCancerArticlesmedicine.diseaseMolecular medicinetrastuzumabOncologyCohortTubular AdenocarcinomaImmunohistochemistrygastric adenocarcinomabusinessmedicine.drug
researchProduct

Aggressive Intrinsic Subtypes in Breast Cancer: A Predictor of Guideline Adherence in Older Patients With Breast Cancer?

2015

Treatment side effects, comorbidities, and guideline-adherent treatment (GL+) influence the oncologic outcome of older breast cancer patients (oBCP) (age ≥ 70 years). The focus of this analysis was to investigate the associations among tumor characteristics, guideline adherence, and outcome and to compare these associations between younger breast cancer patients (yBCP) (age 50-69 years) and oBCP.This is a retrospective multicenter cohort study with 17 participating certified breast cancer centers. The analysis of 10,897 patient records collected from 1992 to 2008 for GL+ and clinical outcome was performed. Tumor and patient characteristics and their associations with GL+ were compared betwe…

OncologyCancer Researchmedicine.medical_specialtyPatient characteristicsBreast NeoplasmsHER2/neuCohort StudiesBreast cancerOlder patientsInternal medicinemedicineHumansStage (cooking)AgedRetrospective StudiesGynecologybiologybusiness.industryGuideline adherenceMiddle Agedmedicine.diseaseOncologyPractice Guidelines as Topicbiology.proteinFemaleGuideline AdherencebusinessTamoxifenmedicine.drugCohort studyClinical Breast Cancer
researchProduct

Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis o…

2013

e20028 Background: Adjuvant high-dose interferon (HDI) treatment of patients (pts) with malignant melanoma (MM) consists of 4 weeks intravenous (IV) induction with 20 MU/m² interferon (IFN) alpha 2b followed by 11 months of 10 Mio IU/m² IFN subcutaneously (sc). It is unclear whether both parts of the regimen are mandatory for the efficacy of HDI treatment. The adjuvant phase III trials DeCOG MM-ADJ-5 and the Italian Melanoma Intergroup (IMI) trial evaluated intermittent IV HDI (iHDI) regimens as compared to standard HDI. In both trials, the experimental arm consisted of iHDI for 3 or 4 cycles, respectively. To gain more insight into the role of iHDI in the adjuvant setting we performed a p…

OncologyCancer Researchmedicine.medical_specialtyPhase iii trialsbusiness.industryMelanomamedicine.medical_treatmentAlpha interferonmedicine.diseasePooled analysisOncologyInterferonInternal medicineImmunologymedicineStage (cooking)businessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct

ErbB-3 predicts survival in ovarian cancer.

2006

Background HER3 (erbB-3) is a member of the epidermal growth factor receptor (EGFR) family. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3′-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). Here, we studied a possible association between HER3 expression and prognosis in patients with ovarian cancer. Methods Tumor tissue of 116 consecutive patients diagnosed with primary epithelial ovarian cancer between 1986 and 1995 was analyzed immunohistochemically for HER3 expression. A possible influence of HER3 expression on survival was studied by multivariate Cox regression adjusting for …

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-3Receptor ErbB-2ErbBPredictive Value of TestsInternal medicinemedicineBiomarkers TumorOdds RatioHumansEpidermal growth factor receptorStage (cooking)Protein kinase BNeoplasm StagingProportional Hazards ModelsGynecologyOvarian NeoplasmsbiologyProportional hazards modelbusiness.industryHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisUp-RegulationGene Expression Regulation NeoplasticOncologyMultivariate Analysisbiology.proteinFemaleSignal transductionOvarian cancerbusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use

2015

Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value iden…

OncologyCancer Researchmedicine.medical_specialtyTreatment regimenbusiness.industryPatient riskTransferabilityCancerGene signaturemedicine.diseaseBioinformaticsOncologyNeuroblastomaInternal medicinemedicineStage (cooking)businessGeneInternational Journal of Cancer
researchProduct

Addressing the importance of melanoma tumor‑infiltrating lymphocytes in disease progression and clinicopathological characteristics

2021

Tumor-infiltrating lymphocytes (TILs) in primary cutaneous melanoma are considered to represent the host's antitumor immunological response; however, whether there are associations between TIL grade and histopathological characteristics and disease survival remains controversial. BRAF mutational status has been established as a routine screening method in advanced malignant melanoma, and worse prognosis rates have been demonstrated in patients harboring BRAF mutations. However, the general impact of BRAF mutational status on survival and histopathological characteristics is still debated. The aim of the present study was to compare the value of the assessment of TIL grade in stages I-II nod…

OncologyCancer Researchmedicine.medical_specialtyTumor-infiltrating lymphocytesbusiness.industryMelanomaHazard ratioCancerBRAF V600ArticlesDiseasemedicine.diseaseSuperficial spreading melanomaOncologytumor infiltrating lymphocytesInternal medicineCutaneous melanomamelanomahistopathologymedicineStage (cooking)businessneoplasmsMolecular and Clinical Oncology
researchProduct